Ch.6 Patient-facing materials | JPMA Guide Commentary | Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence

This chapter deals with materials that reach patients rather than healthcare professionals. When the recipient changes, the rules change too. A specialist can return to the package insert or the review report and judge for themselves whether a piece of information holds up; a patient has no such footing. So in this domain the harder question is not what to include but what to leave out, and where to stop. Read against the spirit of the foreword, the duty to complement the electronic package insert as the original, and to avoid not only falsehood but the seed of misunderstanding, is tested most severely in the materials that sit closest to the patient.

Patient-facing materials fall into two kinds: medication-guidance materials, which patients read themselves as an aid to taking their medicine, and patient-explanation materials, which healthcare professionals use when explaining things to patients. Both serve patients, but because the reader and the manner of use differ, the permitted scope of content differs as well. Blur this distinction while piling on information, and the material slides into advertising.

01The line shifts with who receives the material

The axis that separates the two is simply this: who directly receives and reads the material. Medication-guidance materials are built on the premise that the patient reads them. Patient-explanation materials are kept by a healthcare professional and shown to the patient as an aid to dialogue. The former aims for "the patient does not err even when alone"; the latter aims to "accurately support the professional's explanation." Because the aims differ, so does the depth of information that may be entered and the kind of clinical data that may be attached.

Two premises are shared. Both must comply with the Pharmaceuticals and Medical Devices Act and related laws, and both must state the company name. Health information whose source is hidden loses credibility by that fact alone. Showing who issued the material, and bears responsibility for it, is the minimum line of patient protection.

02Medication-guidance materials — confined to what is needed for safe use

Medication-guidance materials are made for patients who are actually using a particular drug, to help them keep using it appropriately. At the center sits the information needed for safe use: how to take the medicine, precautions for use, cautions about adverse reactions, how to store it, and the like, the practical information that lets a patient avoid danger and not get lost in daily dosing.

Stop effect claims at "the minimum"

Effect is described only at the necessary minimum, or through a figure conveying an image of the effect. Concrete clinical data, numbers and trial results, are not included. This is not to withhold information but to prevent patients from judging their own condition and adjusting their dosing on their own. A figure like "effective in X%" carries context for a specialist, but for a patient it easily invites the mistaken expectation "it should work just as well for me," or the opposite self-judgment "if it isn't working, I'll stop." A statistically significant difference is not the same as clinical significance, and an average effect does not transfer directly to any one patient. That gap must not be left for a single patient to fill.

Even within drug-effect figures, a conceptual diagram conveying an image of the effect and a graph showing trial results in numbers are different things. The former is allowed; the latter does not belong in medication-guidance materials. The test is not "it's only a figure, so it's fine" but "am I handing concrete clinical data directly to a patient?"

Referring to other companies' products; stating the intended recipient

Only where reference to another company's product is genuinely necessary, as for co-administration cautions, it is made in principle by the generic name. Bringing in a brand name risks turning the mention into commentary on a competitor dressed as comparison. Narrow the scope by necessity, keep the wording to the generic name — this two-step guard separates the provision of safety information from criticism of others.

Further, to keep the intended recipient from being mistaken, the material states plainly "To those taking (using) ___." Putting on the face of the material that it is for people already using the drug cuts off any reuse as de facto solicitation of those not yet using it. This too is a concrete form of the foreword's spirit of avoiding misunderstanding.

03Patient-explanation materials — supporting the professional's explanation

Patient-explanation materials are used when a healthcare professional explains things to a patient. They may therefore carry, as needed, content that goes further than medication-guidance materials: explanation of the disease state, coping methods, product information, how to take the medicine, adverse reactions, storage, and so on, within the range that helps understanding of the drug and the illness. Yet this depth is permitted precisely because a professional stands in between; it does not mean one may write freely.

Coping methods: fair and objective, within what is usually anticipated

When explaining the disease state and coping methods, write what is usually anticipated, fairly and objectively. Exaggerating one particular coping method, or drawing the picture of the disease in a way convenient to one's own product, becomes inducement wearing the face of explanation. The aim is that the patient understands their illness correctly, not that they are steered toward a product.

Clinical results — what may and may not be shown

When clinical results are handled, they are stated on a scientific basis, accurately, fairly, and objectively. Showing efficacy and safety in good balance is the crux. Lining up only the success stories while not touching adverse reactions or limits comes close to falsehood as a whole, even if every sentence is factual. Safety information is disclosed even when unfavorable to one's own product — this is the discipline of anyone handling evidence, and it cannot be conceded even in patient-facing materials.

Patient-explanation materials do not carry the results of comparative clinical trials (other than placebo-controlled ones). Head-to-head results between active drugs are information a specialist should read with context; brought into the setting of patient explanation, they tend to leave only the bare impression of "which is better." Placebo-controlled results, by contrast, are basic information showing the drug's own efficacy, and so are placed outside this restriction. How far the reach of comparison is allowed is the line that divides the two.

Point	Medication-guidance	Patient-explanation
Main reader	The patient	Healthcare professional (used to explain to the patient)
Effect / clinical data	Minimum needed / image figure only. No concrete clinical data	On a scientific basis, efficacy and safety in balance
Comparative trials (other than placebo-controlled)	—(no clinical data at all)	Not included
Other companies' products	Only when needed; generic name in principle	Generic name in principle
Indication / dosage	Within what is needed for safe use	No off-approval content; no reference information
Required statements	"To those taking (using) ___" + company name	"For healthcare professionals" + company name

04Do not step beyond the approved frame — restraint in indication and dosage

In patient-explanation materials, content outside the approved range of indication and dosage is not included. Beyond that, hinting at off-approval use under the guise of "reference information" is also avoided. Information of the form "not formally recognized, but it can also be used this way" may exist as material for a professional's judgment, yet handed out as a material it can promote off-label use. A material placed before a patient stays inside the public frame of approval. This is compliance with law and, at the same time, the foreword's stance of governing even unwritten territory by higher norms.

Prefaces like "for reference" or "according to the literature" are no indulgence for carrying off-approval information. The approved range in patient-explanation materials cannot be widened by a turn of phrase.

05State what must be stated, without fail

Common to both materials, the company name and a statement of the material's character are indispensable. For medication-guidance materials, "To those taking (using) ___"; for patient-explanation materials, "For healthcare professionals," shown on the face of it. Letting the material speak for whom and for what it exists — this small step keeps it from drifting into an unintended setting and breeding misunderstanding. The habit of making source and purpose explicit is the last fence for patient protection.

In closing

The difficulty of patient-facing materials is that correctness of information is not enough. Even when every sentence is factual, the quantity and arrangement can leave a mistaken impression, and if a patient changes their dosing by their own judgment, the material has done harm. So medication-guidance materials are confined to what is needed for safe use, and patient-explanation materials are kept within the range that accurately supports the professional's explanation.

Keep effect claims modest, disclose safety even when unfavorable, and do not exceed the reach of comparison or the frame of approval. Let the material state plainly who reads it and how it is used. Each of these implements, at the place closest to the patient, the foreword's spirit of avoiding not only falsehood but misunderstanding.

Case studies — the "it isn't written, so…" mindset, and how each lands

Patient-facing materials are read without a healthcare professional present. Below are four escalating schemes that exploit the rule that "clinical data is prohibited" and "efficacy language must be minimal" — using the gap to plant reassurance instead.

GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)

The scheme: "No numbers on a medication-guidance leaflet — fine. But I can print 'chosen by physicians for years' alongside a satisfied patient illustration on the cover. The rule only bans figures."

Verdict: Avoiding numbers while implying physician preference still influences treatment decisions. It runs against the foreword's demand to "not just avoid falsehood but also cut off misunderstanding at the root." The correct approach: strip every efficacy and preference claim; confine the leaflet to dosing instructions and precautions.

GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)

The scheme: "Clinical data cannot appear. But writing 'effects often begin to show around week N' is prose, not a figure — so it's allowed. Patients get the same expectation a trial result would create, with no numbers in sight."

Verdict: Verbal reformulation of a trial finding still delivers trial-grade expectation to the patient. The prohibition on figures exists precisely to prevent patients from self-adjusting dosing based on perceived efficacy timelines. Substituting words for numbers does not change the purpose or the harm. This reads as a de facto clinical-data disclosure and is likely in breach of the Medical Device and Drug Act advertising standards.

GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)

The scheme: "Under 'medication guidance' I can add an off-label data column as 'reference information.' European trial results for an unapproved dosage sit in a sidebar — patients will read it and may self-escalate."

Verdict: Providing information that goes beyond the approved indication or dosage breaches Advertising Standards 4-3(1) and 4-3(4), which bar expressions beyond the approved range and which the MHLW explanatory notice treats as interpreting Article 66(1) of the PMD Act. Patients who act on off-label information face direct safety risk. The JPMA Code requires materials to stay within approved content. Labelling the piece "medication guidance" provides no shelter.

BLACK — Breaching the explicit text (a plain violation of the provision itself)

The scheme: "I'll call it a 'patient-explanation aid' and stock it in the waiting room for anyone to pick up. It's just a verbatim extract from the package insert — accurate, objective, can't be wrong."

Verdict: Patient-explanation aids are designed for healthcare professionals to hand to patients during a consultation, not for unmediated waiting-room distribution. Mass placement violates the stipulated distribution format. Reaching patients who are not yet on the drug also constitutes potential unlicensed advertising under the PMD Act. Factual accuracy is not a defence against a distribution violation.

Improper intent by implication — three scopes of "insinuating" without stating it

Patient-facing materials operate under a firm rule: they must not actively encourage a visit to a healthcare facility. Yet the choice of a single word, the ordering of adjacent clauses, or the overall structural weight of a document can nudge patients toward clinic visits without a single explicit directive. The three examples below use a medication-use guide as the vehicle.

Implication 1 — Local: carried in a single word or sentence

How it is built: "If your symptoms concern you, please consult a healthcare provider promptly."

Intent that can be read: The word "promptly" carries a sense of urgency. The text never says "go now," but the modifier implies that delay is risky — effectively recommending a visit.

Verdict: A medication-use guide is for patients already on the medicine. Any language that promotes a first or follow-up visit converts it into promotional material. "Promptly" is the single word doing the implying. The correct approach is to list the prescriber as a contact for adverse reactions only, without urgency framing.

Implication 2 — Adjacent: read across neighboring clauses

How it is built: "This medicine stabilises blood pressure. Fluctuating blood pressure can place strain on the heart and brain. Regular clinic visits help confirm your condition."

Intent that can be read: Each sentence is factually defensible in isolation. Placed in sequence — benefit of the drug, disease risk, clinic attendance — they form an implied argument: you need this drug and you need to keep attending the clinic to stay safe.

Verdict: The sequence creates a causal chain that the individual sentences do not. Decisions about follow-up frequency belong to the prescriber. Replace "Regular clinic visits help confirm your condition" with "If you notice any changes, consult your doctor," or remove it entirely.

Implication 3 — Whole-context: arising from the document as a whole

How it is built: A medication-use guide opens with "to keep your condition under control," then devotes full chapters to "how symptoms develop," "the risks of leaving symptoms untreated," and "the role of this medicine," closing with "for anything you are unsure about, visit your healthcare facility."

Intent that can be read: No individual section violates a rule. The document as a whole, however, centres on disease threat rather than safe medicine use, reinforcing that the patient must remain in the medical system — under this medicine — to avoid harm.

Verdict: The structural principle for medication-use guides is to limit content to information needed for safe use. A chapter structure built around disease risk operates as pressure to maintain treatment attendance even when each sentence is accurate. The guide must be reorganised around the practical axis: how to take, precautions, handling side effects, storage.